Previously, the JAK2 mRNA level has been linked to an increased T-cell signature and improved survival in primary breast cancers.25 One hypothesis is that anti-tumor effects of ruxolitinib may have been balanced by inhibition of host anti-tumor immune response. The gene discussed is JAK2; the disease is neoplasm.